Regenlab USA Inc.

S-1 filed

DRS/A amended

Regenlab USA Inc. reported significant revenue growth in 2026, driven by a 42% increase in total revenue to $16.357 million for the three months ended March 2026 compared to $11.492 million in the same period in 2025. The U.S. market saw a major shift, with revenue contribution rising from 20% to 50% due to an exclusive distribution agreement with MiMedx for wound care products, which generated $3.75 million in revenue. Gross profit improved by $5.2 million, and operating income turned positive at $4.626 million in Q1 2026 compared to a net loss of $0.651 million in Q1 2025. The company also highlighted expanded R&D efforts for market access in the U.S. and Europe, with key projects including the RegenMatrix clinical study and Cellular Matrix RL-04 initiative.

DRS/A amended

Regenlab USA Inc. reports mixed financial performance in 2025 with $49.17M in revenue, up 1.6% from 2024, but operating income dropped 80.59% to $0.68M due to factory relocation costs and increased R&D spending. Key R&D initiatives include RegenMatrix clinical trials, Cellular Matrix US market access (RL-04), and BBI Implants development. The company faces liquidity challenges, disclosing a $1.85M cash balance and negative operating cash flow, raising concerns about its ability to continue as a going concern. Significant partnerships include MiMedx and OPKO Health for product distribution.

DRS/A amended

Regenlab USA Inc. reports improved financial performance in 2024 with revenue increasing to $48.38M (+1.2% YoY), driven by international growth in Europe and select markets, while U.S. sales declined due to channel realignment. The company highlights expanded gross margins (71.4%) from high-margin PRP+HA products, cost optimization reducing G&A and marketing expenses by $1.2M, and increased R&D investment to $3.85M. Strategic partnerships like OPKO Health (Spain/Europe) and MiMedx are expected to restore U.S. growth. Key product lines include PRP kits (61% of revenue) and CellularMatrix (27%), with a focus on regenerative biologics and tissue engineering platforms.

DRS filed

Regenlab USA Inc. reported improved financial performance in 2024, with revenue increasing to $48.38M (+1.2% YoY), driven by growth in Europe and international markets, while U.S. sales declined due to channel realignment. The company achieved a net income of $1.01M in 2024 compared to a $2.95M loss in 2023, supported by cost optimization, gross margin expansion to 71.4%, and R&D investments. Strategic partnerships with MiMedx and OPKO Health, along with new product launches, are expected to drive future growth. The company also secured a $5M SBA-guaranteed loan and remains focused on expanding its regenerative biologics portfolio.